Chemical formula: C₂₃H₂₇Cl₂N₃O₂ Molecular mass: 448.385 g/mol PubChem compound: 60795
It has been proposed that aripiprazole’s efficacy in schizophrenia and Bipolar I Disorder is mediated through a combination of partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism of serotonin 5-HT2A receptors.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N05AX12 | Aripiprazole | N Nervous system → N05 Psycholeptics → N05A Antipsychotics → N05AX Other antipsychotics |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| ABILIFY Tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| ABILIFY Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Aripiprazole is an active ingredient of these brands:
Australia (AU)Canada (CA)Finland (FI)France (FR)Germany (DE)Ireland (IE)Japan (JP)Mexico (MX)Netherlands (NL)New Zealand (NZ)Poland (PL)Singapore (SG)Turkey (TR)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
